Sauzanne Khalilieh and colleagues report a proof-of-concept clinical trial that demonstrates that targeting the pro-inflammatory cytokine interleukin 23 (IL-23) with tildrakizumab, an antibody that binds the p 19 subunit of IL-23, leads to symptomatic improvement of disease in patients with moderate to severe psoriasis.
展开▼
机译：Sauzanne Khalilieh及其同事报告了一项概念验证的临床试验，该试验表明，将结合IL-23 p 19亚基的抗体tildrakizumab靶向促炎性细胞因子白介素23（IL-23），可导致症状改善。中重度牛皮癣患者的疾病。
展开▼
